Literature DB >> 9258812

Genomic alterations in human glioma cell lines detected by restriction landmark genomic scanning.

M Nakamura1, N Konishi, S Tsunoda, Y Hiasa, T Tsuzuki, K Takemura, K Kobitsu, T Sakaki.   

Abstract

Restriction landmark genomic scanning (RLGS) is a 2-dimensional gel analysis capable of detecting amplifications, deletions and rearrangements in genomic DNA. Using RLGS, we examined genomic DNA from each of 6 human-derived malignant glioma cell lines and from normal brain tissue samples. RLGS allows us to screen genomic DNAs as approximately 2,000 landmark sites in one procedure without any polymorphic markers. The resulting 2,000 spots in tumor samples were compared with those in normal brain. Six spots common to 5 of the 6 cell lines showed intensified signal, suggesting amplification of a tumor-specific DNA fragment. In addition, 25 spots common to 5 of the 6 lines showed a decrease in signal intensity, conversely indicating allelic loss of homozygous deletion. These results imply the existence of consistent genetic alterations in human glioma.

Entities:  

Mesh:

Year:  1997        PMID: 9258812     DOI: 10.1023/a:1005714811327

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  A genomic scanning method for higher organisms using restriction sites as landmarks.

Authors:  I Hatada; Y Hayashizaki; S Hirotsune; H Komatsubara; T Mukai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  Cloning of no tI-cleaved genomic DNA fragments appearing as spots in 2D gel electrophoresis.

Authors:  H Nagai; M Pongliktmongkol; Y S Kim; H Yoshikawa; K Matsubara
Journal:  Biochem Biophys Res Commun       Date:  1995-08-04       Impact factor: 3.575

3.  Proto-oncogene abnormalities and their relationship to tumorigenicity in some human glioblastomas.

Authors:  H S U; P Y Kelley; J D Hatton; J Y Shew
Journal:  J Neurosurg       Date:  1989-07       Impact factor: 5.115

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.

Authors:  T Tsuzuki; S Tsunoda; T Sakaki; N Konishi; Y Hiasa; M Nakamura
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

6.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

7.  Genomic aberrations in human hepatoblastomas detected by 2-dimensional gel analysis.

Authors:  H Nagai; H Tsumura; M Ponglikitmongkol; Y S Kim; K Matsubara
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

8.  The retinoblastoma gene is involved in malignant progression of astrocytomas.

Authors:  J W Henson; B L Schnitker; K M Correa; A von Deimling; F Fassbender; H J Xu; W F Benedict; D W Yandell; D N Louis
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

9.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

10.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

View more
  2 in total

Review 1.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.